Please login to the form below

Not currently logged in
Email:
Password:

HTA guidance from NICE, the SMC and the AWMSG

Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).

Provided by Guidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.

British Association of Dermatologists' guidelines for biologic interventions for psoriasis (update)

June 2017: Independent professional body guideline

Guidelines on the management of sexual problems in men: the role of androgens–update (British Society for Sexual Medicine)

June 2017: Independent professional body guideline

Parkinson’s disease (update)

June 2017: NICE Clinical Guideline

Psoriasis (Primary Care Dermatology Society)

June 2017: Independent professional body guideline

Rhinitis management guidelines—update (British Society for Allergy and Clinical Immunology)

June 2017: Independent professional body guideline

Liraglutide for weight management

June 2017: NICE Evidence summary: new medicines

Liver disease

June 2017: NICE Quality Standard

Multimorbidity

June 2017: NICE Quality Standard

Violence and aggression

June 2017: NICE Quality Standard

Air pollution: outdoor air quality and health

June 2017: NICE Public Health Guidance

Visit the Guidelines website

NICE relents on Kadcyla after Roche pricing negotiations

NICE relents on Kadcyla after Roche pricing negotiations 21 Jun 2017

HER2-positive breast cancer therapy to be made available on the NHS in England

NICE rejects Pfizer's antibody drug for leukaemia

NICE rejects Pfizer's antibody drug for leukaemia 15 Jun 2017

Trial shows no survival benefit from Besponsa compared to current treatment

NICE turns down Opdivo for head and neck cancer

NICE turns down Opdivo for head and neck cancer 11 Apr 2017

BMS’s nivolumab proves too costly for the NHS

NICE knocks-back Shire's pancreatic cancer drug Onivyde

NICE knocks-back Shire's pancreatic cancer drug Onivyde 28 Mar 2017

Final guidance rules it's not a cost-effective use of NHS resources

NICE backtracks on Biogen's multiple sclerosis drug Zinbryta

NICE backtracks on Biogen's multiple sclerosis drug Zinbryta 17 Mar 2017

Recommends the treatment after new cost effectiveness and a discount provided

More news from PMLiVE on NICE, the SMC and the AWMSG

MGP’s Guidelines brand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. Through Guidelines, Guidelines for Nurses and Guidelines in Practice, MGP connect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.

To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Infographics